申请人:Asahi Kasei Kogyo Kabushiki Kaisha
公开号:US05658923A1
公开(公告)日:1997-08-19
An azepine compound of the formula ##STR1## wherein R is (a) ##STR2## in which R.sup.1 is hydrogen, lower alkyl, lower alkoxy, hydroxy, halogen, or optionally substituted phenyl, and n is 0 or 1, (b) cycloalkyl of C.sub.5-8 which is optionally substituted by lower alkyl, (c) norbornyl, (d) bicyclo[3.3.1]nonyl, (e) naphthyl, (f) 1,3-benzoxolyl, (g) pyridyl, or (h) thienyl, m is an integer of 0-4, and C* is an asymmetric carbon, and nontoxic salts thereof, processes for producing the same, and therapeutic agents containing the same as the active ingredient for treating diseases related to .sigma.-receptor. The compound (1) and nontoxic salts thereof have a high affinity for .sigma.-receptor but scarcely any affinity for other receptors, thus being utilized for treating diseases related to .sigma.-receptor, such as schizophrenia.
化合物为azepine,化学式为##STR1##其中R为(a)##STR2##其中R.sup.1为氢,低烷基,低烷氧基,羟基,卤素或可选取代苯基,n为0或1,(b) C.sub.5-8的环烷基,可选取代低烷基,(c) norbornyl,(d) bicyclo [3.3.1]nonyl,(e) naphthyl,(f) 1,3-benzoxolyl,(g) pyridyl或(h) thienyl,m为0-4的整数,C*为不对称碳,以及其无毒盐,生产过程以及包含其作为活性成分的治疗剂,用于治疗与.sigma.-受体相关的疾病。化合物(1)及其无毒盐对.sigma.-受体具有高亲和力,但几乎没有亲和力与其他受体结合,因此可用于治疗与.sigma.-受体相关的疾病,如精神分裂症。